The cost of bringing new prescription drugs to market has skyrocketed in recent years while the return for investors is significantly lower, according to a study released on Monday by Bain & Co. consulting firm.
The cost of bringing new prescription drugs to market has skyrocketed in recent years while the return for investors is significantly lower, according to a study released on Monday by Bain & Co. consulting firm.
